摘要
血脑屏障(BBB)由脑毛细血管内皮细胞构成,可以阻止一些药物分子进入大脑,尤其是亲水性分子。像纳米粒子一样的先进分子载体都有允许治疗性蛋白和遗传分子进入中枢神经系统(CNS)的潜力。采用靶向技术,配体或者单克隆分子与脑毛细血管内皮细胞腔面表达的亲和蛋白偶联,纳米粒子可以设计成能够通过脑内皮细胞,或者甚至可以透过内皮细胞导致从血液向脑内转运。目前,抗转铁蛋白受体的结合铁转运蛋白或抗体显示为在血脑屏障中最可行的分子靶向目标。这篇文章综述了脑毛细血管内皮细胞的纳米粒子强化材料,纳米粒子也许通过脑内皮细胞进入和转运,及由脑毛细血管基底膜构成的胞外蛋白三维网状结构是如何抑制;挑战了包裹的纳米粒子大分子是如何通过血脑屏障进行转运的可能性。
关键词: 基膜,血脑屏障,胞吞作用,纳米粒子,神经退行性变,OX26,转胞吞作用,转铁蛋白
Current Medicinal Chemistry
Title:Accessing Targeted Nanoparticles to the Brain: The Vascular Route
Volume: 21 Issue: 36
Author(s): A. Burkhart, M. Azizi, M.S. Thomsen, L.B. Thomsen and T. Moos
Affiliation:
关键词: 基膜,血脑屏障,胞吞作用,纳米粒子,神经退行性变,OX26,转胞吞作用,转铁蛋白
摘要: The blood-brain barrier (BBB), formed by brain capillary endothelial cells, prevents the entry of several drug molecules to the brain, especially molecules hydrophilic in nature. Advanced drug carriers like nanoparticles share the potential to allow entry of therapeutic proteins and genetic molecules into the central nervous system (CNS). Taking a targeting approach by conjugating molecules acting as ligands or monoclonal antibodies with affinity for proteins expressed on the luminal side of brain capillary endothelial cells, the nanoparticles can be designed to enable transport into the brain endothelium, or perhaps even through the endothelium leading to blood to brain transport. Currently, the iron-binding protein transferrin or antibodies raised against the transferrin receptor denote the most feasible molecule for targeting purposes at the BBB. This manuscript reviews the targetability of nanoparticles to the brain capillary endothelial cells, how nanocarriers may enter and transfer through the brain endothelium, and how likely restraints denoted by the threedimensional mesh of the extracellular proteins forming the brain capillary basement membrane challenge the possibilities for enabling transport of large molecules through the BBB encapsulated in nanoparticles.
Export Options
About this article
Cite this article as:
Burkhart A., Azizi M., Thomsen M.S., Thomsen L.B. and Moos T., Accessing Targeted Nanoparticles to the Brain: The Vascular Route, Current Medicinal Chemistry 2014; 21 (36) . https://dx.doi.org/10.2174/0929867321666140716095317
DOI https://dx.doi.org/10.2174/0929867321666140716095317 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Inflammatory Response in Stroke Associated Programmed Cell Death
Current Neuropharmacology A Molecular Link Between Diabetes and Breast Cancer: Therapeutic Potential of Repurposing Incretin-based Therapies for Breast Cancer
Current Cancer Drug Targets Matter of Life and Death: the Pharmacological Approaches Targeting Apoptosis in Brain Diseases
Current Pharmaceutical Design Carbon Monoxide and the Brain: Time to Rethink the Dogma
Current Pharmaceutical Design Ex Vivo Liver – Directed Gene Therapy for the Treatment of Metabolic Diseases: Advances in Hepatocyte Transplantation and Retroviral Vectors
Current Gene Therapy Pexelizumab, an Anti-C5 Complement Antibody for Primary Coronary Revascularization: A New Insight from Old Versions
Cardiovascular & Hematological Disorders-Drug Targets Chemokines and Brain Functions
Current Drug Targets - Inflammation & Allergy Cysteinet Dysregulation in Muscular Dystrophies: A Pathogenic Network Susceptible to Therapy
Current Medicinal Chemistry New Sides of Aldosterone Action in Cardiovascular System as Potential Targets for Therapeutic Intervention
Current Drug Targets Treating Neonatal Brain Injury - Promise and Inherent Research Challenges
Recent Patents on Inflammation & Allergy Drug Discovery Mitochondria-targeted Resveratrol Derivatives Act as Cytotoxic Pro-oxidants
Current Pharmaceutical Design The Therapeutic Potential of Neuro-EPO Administered Nasally on Acute Cerebrovascular Disease
Current Psychopharmacology Antibody Mediated Rejection in Pig-To-Nonhuman Primate Xenotransplantation Models
Current Drug Targets - Cardiovascular & Hematological Disorders Anti-Oxidants in Parkinson’s Disease Therapy: A Critical Point of View
Current Neuropharmacology Nuclear Imaging of Post-infarction Inflammation in Ischemic Cardiac Diseases - New Radiotracers for Potential Clinical Applications
Current Radiopharmaceuticals Platelets in Atherothrombosis: New and Evolving Roles
Current Pharmaceutical Design The Role of Autophagy in the Pathogenesis of Ischemic Stroke
Current Neuropharmacology Intracranial Aneurysms in Sickle Cell Disease
Current Neurovascular Research AMPK in Neurodegenerative Diseases: Implications and Therapeutic Perspectives
Current Drug Targets Comparison of Pharmacokinetics of Cyclosporine A in Cadaveric and Living- Related Renal Transplant Recipients and in an Experimental Rat Model of Renal Failure
Drug Metabolism Letters